Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Trial ID or NCT#
NCT04088890
Status
RECRUITING
Purpose
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Official Title
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Matthew Frank
Blood and marrow transplant specialist,
Hematologist-Oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Andrew Rezvani, M.D.
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Lori Muffly
Hematologist,
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Hematologist-Oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Crystal Mackall
David Miklos
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Hematologist,
Medical oncologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Surbhi Sidana, MD
Blood and marrow transplant specialist,
Hematologist-Oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Contact us to find out if this trial is right for you.
Contact
Juliana Craig
650-736-0912
View on ClinicalTrials.gov